{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:16:39Z","timestamp":1790270199824,"version":"4.1.0"},"publisher-location":"Cham","reference-count":24,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319914381","type":"print"},{"value":"9783319914398","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-91439-8_14","type":"book-chapter","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T20:25:48Z","timestamp":1533155148000},"page":"285-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Acalabrutinib, A Second-Generation Bruton\u2019s Tyrosine Kinase Inhibitor"],"prefix":"10.1007","author":[{"given":"Katharina","family":"Kriegsmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kriegsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"14_CR1","unstructured":"Agency EM (2017) Ibrutinib [monograph on the internet]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003791\/human_med_001801.jsp&mid=WC0b01ac058001d124"},{"key":"14_CR2","unstructured":"AstraZeneca (2017a) Prescribing information of CALQUENCE (acalabrutinib) [monograph on the internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf"},{"key":"14_CR3","unstructured":"AstraZeneca (2017b) S FDA approves AstraZeneca\u2019s Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma [monograph on the internet]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2017\/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html"},{"key":"14_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/jpet.117.242909","volume":"363","author":"T Barf","year":"2017","unstructured":"Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A (2017) Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther 363:240\u2013252","journal-title":"J Pharmacol Exp Ther"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bcmd.2015.06.016","volume":"55","author":"K Bojarczuk","year":"2015","unstructured":"Bojarczuk K, Bobrowicz M, Dwojak M, Miazek N, Zapala P, Bunes A, Siernicka M, Rozanska M, Winiarska M (2015) B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells Mol Dis 55:255\u2013265","journal-title":"Blood Cells Mol Dis"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374:323\u2013332","journal-title":"N Engl J Med"},{"key":"14_CR7","unstructured":"ClinicalTrials.gov (2017) Acalabrutinib (ACP-196) clinical trials [monograph on the internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=acalabrutinib&cntry1=&state1=&Search=Search"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS (2017) Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31:2075\u20132084","journal-title":"Leukemia"},{"key":"14_CR9","unstructured":"FDA (2017) FDA grants accelerated approval to acalabrutinib for mantle cell lymphoma [monograph on the internet]. Available from: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm583106.htm"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.3324\/haematol.2017.169334","volume":"102","author":"J Golay","year":"2017","unstructured":"Golay J, Ubiali G, Introna M (2017) The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica 102:e400\u2013e403","journal-title":"Haematologica"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"e0159607","DOI":"10.1371\/journal.pone.0159607","volume":"11","author":"BK Harrington","year":"2016","unstructured":"Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC (2016) Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-hodgkin lymphoma. PLoS ONE 11:e0159607","journal-title":"PLoS ONE"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","volume":"23","author":"SEM Herman","year":"2017","unstructured":"Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Mantel R, Smith LL, McClanahan F, Harrington BK, Colomer D, Covey T, Byrd JC, Izumi R, Kaptein A, Ulrich R, Johnson AJ, Lannutti BJ, Wiestner A, Woyach JA (2017) The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic Leukemia. Clin Cancer Res 23:2831\u20132841","journal-title":"Clin Cancer Res"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","volume":"3","author":"P Kapoor","year":"2017","unstructured":"Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB (2017) Diagnosis and Management of Waldenstrom Macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol 3:1257\u20131265","journal-title":"JAMA Oncol"},{"key":"14_CR14","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA (2016) Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 127:1559\u20131663","journal-title":"Blood"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1158\/1078-0432.CCR-17-0650","volume":"23","author":"CU Niemann","year":"2017","unstructured":"Niemann CU, Mora-Jensen HI, Dadashian EL, Krantz F, Covey T, Chen SS, Chiorazzi N, Izumi R, Ulrich R, Lannutti BJ, Wiestner A, Herman SEM (2017) Combined BTK and PI3Kdelta inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL mouse model. Clin Cancer Res 23:5814\u20135823","journal-title":"Clin Cancer Res"},{"key":"14_CR16","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","volume":"129","author":"A Noy","year":"2017","unstructured":"Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R (2017) Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma. Blood 129:2224\u20132232","journal-title":"Blood"},{"key":"14_CR17","doi-asserted-by":"crossref","unstructured":"Patel VK, Lamothe B, Ayres ML, Gay J, Cheung J, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V (2017) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: Similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia","DOI":"10.1038\/leu.2017.321"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/13543784.2017.1384814","volume":"26","author":"P Robak","year":"2017","unstructured":"Robak P, Robak T (2017) Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opin Investig Drugs 26:1249\u20131265","journal-title":"Expert Opin Investig Drugs"},{"key":"14_CR19","unstructured":"Thompson PA, Burger JA (2017) Bruton\u2019s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs 1\u201312"},{"key":"14_CR20","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.3324\/haematol.2017.168930","volume":"102","author":"A Vidal-Crespo","year":"2017","unstructured":"Vidal-Crespo A, Rodriguez V, Matas-Cespedes A, Lee E, Rivas-Delgado A, Gine E, Navarro A, Bea S, Campo E, Lopez-Guillermo A, Lopez-Guerra M, Roue G, Colomer D, Perez-Galan P (2017) The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-kappaB mutational status. Haematologica 102:e447\u2013e451","journal-title":"Haematologica"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","volume":"127","author":"HS Walter","year":"2016","unstructured":"Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G (2016) A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 127:411\u2013419","journal-title":"Blood"},{"key":"14_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Liu C, Tsui ST, Liu D (2016a) Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 9:80","journal-title":"J Hematol Oncol"},{"key":"14_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Zhang M, Liu D (2016b) Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol 9:21","journal-title":"J Hematol Oncol"},{"key":"14_CR24","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.18632\/oncotarget.12786","volume":"8","author":"J Wu","year":"2017","unstructured":"Wu J, Zhang M, Liu D (2017) Bruton tyrosine kinase inhibitor ONO\/GS-4059: from bench to bedside. Oncotarget 8:7201\u20137207","journal-title":"Oncotarget"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Hematology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-91439-8_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T05:05:16Z","timestamp":1604725516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-91439-8_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319914381","9783319914398"],"references-count":24,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-91439-8_14","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}